viral
bacteri
respiratori
tract
infect
lead
caus
morbid
mortal
worldwid
despit
develop
vaccin
potent
antibiot
frequent
virus
bacteria
coinfect
host
result
heighten
patholog
sever
ill
compar
singl
infect
bacteri
superinfect
signific
caus
death
everi
influenza
pandem
includ
pandem
review
analyz
epidemiolog
global
impact
viral
bacteri
coinfect
respiratori
tract
emphasi
bacteri
infect
follow
influenza
next
examin
mechan
viral
infect
enhanc
acquisit
sever
bacteri
infect
final
discuss
current
manag
strategi
diagnos
treat
patient
suspect
confirm
viralbacteri
infect
respiratori
tract
investig
interact
viral
bacteri
infect
necessari
develop
new
therapeut
approach
aim
mitig
sever
coinfect
influenza
pneumonia
lead
caus
death
infecti
diseas
unit
state
worldwid
consist
rank
among
top
caus
death
unit
state
result
approxim
death
year
worldwid
estim
million
peopl
succumb
infect
annual
hivaid
tuberculosi
combin
pinpoint
precis
microbiolog
caus
respiratori
infect
impract
infeas
mani
case
often
presum
pneumonia
caus
either
bacteria
respiratori
virus
like
influenza
actual
mani
lower
respiratori
tract
infect
caus
multipl
pathogen
act
synergi
notabl
bacteri
pneumonia
long
appreci
major
complic
influenza
infect
even
advent
antibiot
pandem
bacteria
pneumonia
present
sever
case
requir
hospit
small
autopsi
seri
thu
demonstr
continu
public
health
signific
influenzabacteri
coinfect
despit
avail
vaccin
potent
antibiot
review
discuss
type
coinfect
often
encount
clinic
practic
focu
primarili
coinfect
respiratori
tract
involv
acut
respiratori
virus
communityacquir
bacteri
pathogen
particularli
secondari
bacteri
pneumonia
follow
influenza
first
discuss
epidemiolog
coinfect
follow
brief
overview
find
research
basic
mechan
underli
pathogenesi
viralbacteri
coinfect
final
present
recommend
find
util
clinic
coinfect
clearli
post
therapeut
challeng
clinician
public
health
offici
alik
type
coinfect
encount
practic
viralbacteri
coinfect
regard
common
clinic
signific
problem
although
precis
incid
difficult
determin
varieti
reason
first
mani
case
viralbacteri
coinfect
go
undetect
particularli
outpati
set
common
scenario
patient
present
clinic
histori
presum
viral
upper
respiratori
infect
eg
nasal
congest
rhinorrhea
sore
throat
improv
initi
worsen
day
later
complaint
suspici
bacteri
infect
eg
product
cough
sinu
pain
fever
case
earnest
search
microbiolog
etiolog
often
warrant
second
even
test
perform
diagnost
yield
limit
sensit
current
avail
microbiolog
test
abil
obtain
certain
type
clinic
specimen
eg
sputum
bronchoalveolar
lavag
furthermor
earli
administr
antibiot
appropri
clinic
manag
acut
ill
individu
consider
diminish
yield
bacteri
cultur
reason
interest
turn
adjunct
molecular
test
method
nucleic
acid
amplif
test
naat
eg
viral
respiratori
polymeras
chain
reaction
pcr
panel
direct
antigen
detect
method
eg
streptococcu
pneumonia
legionella
pneumophila
influenza
etc
improv
overal
diagnost
yield
lack
specif
thu
unless
studi
perform
part
larg
clinic
trial
comprehens
protocol
diagnost
test
medic
facil
strict
diagnost
algorithm
place
workup
pneumonia
true
incid
viralbacteri
coinfect
difficult
determin
like
underestim
despit
issu
upper
lower
respiratori
tract
ill
frequent
complic
viral
infect
acut
otiti
media
pediatr
popul
often
observ
viral
outbreak
commonli
respiratori
syncyti
viru
rsv
adenoviru
human
rhinoviru
hrv
coronaviru
recent
identifi
viru
isol
human
respiratori
tract
human
bocaviru
emerg
potenti
import
copathogen
acut
otiti
believ
chang
upper
respiratori
tract
induc
anteced
viral
infect
facilit
bacteri
invas
middl
ear
bacteria
frequent
caus
otiti
streptococcu
pneumonia
moraxella
catarrhali
nontyp
hemophilu
influenza
normal
member
nasopharyng
flora
viral
infect
appear
enabl
bacteria
enter
middl
earand
importantli
flourishresult
diseas
substanti
variat
exist
pattern
viralbacteri
coinfect
report
depend
patient
popul
eg
locat
preval
vaccin
pneumococcu
method
microbiolog
detect
eg
middl
ear
aspir
nasopharyng
swab
viralbacteri
combin
strongli
associ
acut
otiti
media
includ
rhinoviru
rsv
catarrhali
pneumonia
h
influenza
howev
may
also
attribut
fact
rsv
rhinovir
infect
common
pediatr
popul
pneumonia
lower
respiratori
tract
infect
follow
pattern
similar
otiti
increas
rate
pneumonia
appear
coincid
time
period
respiratori
virus
preval
particularli
influenza
rsv
associ
influenza
bacteri
pneumonia
long
recogn
late
earli
bacterium
known
h
influenza
commonli
isol
patient
influenza
infect
believ
etiolog
agent
caus
pandem
sinc
time
virus
bare
discov
retrospect
analysi
specimen
influenza
pandem
reveal
almost
fatal
case
pneumonia
show
evid
bacteri
infect
sinc
epidemiolog
studi
influenza
pandem
epidem
demonstr
incid
pneumonia
peak
concurr
influenza
activ
although
evid
bacteri
infect
present
case
bacteri
cultur
posit
almost
alway
pneumonia
aureu
pyogen
h
influenza
combin
bacteria
gener
secondari
bacteri
pneumonia
complic
influenza
infect
note
sever
prolong
higher
mortal
rate
howev
influenza
season
character
lower
rate
mortal
demonstr
viral
factor
eg
influenza
neuraminidas
current
unknown
factor
respons
determin
incid
sever
influenzabacteri
coinfect
influenza
season
influenza
domin
appear
weakli
associ
higher
rate
invas
pneumococc
infect
may
attribut
higher
neuraminidas
activ
strain
compar
sever
tracheobronch
caus
less
virul
bacteria
anoth
frequent
note
complic
influenza
although
mortal
rate
bacteri
pneumonia
follow
influenza
significantli
declin
centuri
varieti
reason
includ
chang
epidemiolog
influenza
virus
develop
antimicrobi
therapi
vaccin
improv
support
care
bacteri
pneumonia
remain
import
contributor
sever
lethal
influenza
infect
recent
influenza
pandem
bacteri
pneumonia
present
hospit
critic
ill
patient
patholog
microbiolog
analys
fatal
case
show
evid
bacteri
coinfect
rang
microbiolog
data
secondari
pneumonia
studi
present
tabl
ad
bodi
evid
continu
import
influenza
bacteri
coinfect
epidemiolog
studi
report
excess
hospit
rate
pneumococc
pneumonia
pandem
recent
analysi
populationlevel
data
unit
state
pandem
nonpandem
year
reveal
spike
invas
pneumococc
pneumonia
rate
coincid
influenza
activ
furthermor
recent
studi
conduct
unit
state
critic
ill
adult
influenza
infect
report
patient
bacteri
coinfect
higher
mortal
compar
patient
without
continu
intens
focu
influenza
pandem
howev
somewhat
obscur
fact
bacteri
pneumonia
frequent
complic
respiratori
virus
invas
pneumococc
diseas
shown
strongli
correl
rsv
influenza
particularli
among
children
may
part
reflect
higher
preval
rsv
infect
among
children
symptomat
lower
respiratori
infect
number
studi
describ
pattern
viralbacteri
coinfect
children
hospit
communityacquir
pneumonia
cap
popul
rate
viralbacteri
coinfect
usual
rang
higher
rate
younger
age
group
year
age
common
caus
cap
acut
lower
respiratori
tract
infect
lrti
children
pneumonia
mycoplasma
pneumonia
chlamydia
pneumonia
respiratori
virus
although
larg
part
world
h
influenza
aureu
remain
import
caus
thu
type
viralbacteria
coinfect
tend
vari
age
group
geographi
gener
repres
pathogen
commonli
isol
studi
popul
eg
rsv
pneumonia
rhinovirusmycoplasma
although
almost
combin
respiratori
virusbacteri
pathogen
observ
although
widespread
use
vaccin
h
influenza
type
b
larg
elimin
caus
cap
unit
state
highincom
countri
pathogen
caus
estim
sever
fatal
case
childhood
pneumonia
worldwid
adult
viralbacteri
coinfect
rate
among
patient
cap
around
associ
sever
diseas
influenza
rhinoviru
rsv
adenoviru
common
virus
isol
patient
bacteri
cap
epidemiolog
studi
remind
virus
import
etiolog
agent
lrti
well
major
cofactor
develop
sever
bacteri
pneumonia
henc
clinician
counsel
patient
present
initi
respiratori
viral
infect
potenti
risk
develop
secondari
bacteri
infect
return
symptom
worsen
convers
clinician
care
patient
present
evid
sever
lower
respiratori
tract
infect
influenza
known
circul
consid
epidemiolog
bacteri
pathogen
set
consid
empir
treatment
influenza
aureu
addit
usual
regimen
communityacquir
pneumonia
evid
laboratori
mani
investig
shown
enhanc
suscept
bacteri
pathogen
eg
pneumonia
aureu
peak
anywher
day
primari
influenza
infect
persist
day
beyond
murin
model
sequenti
influenza
pneumonia
infect
found
hour
bacteri
challeng
influenzainfect
mice
infect
colonyform
unit
cfu
pneumonia
compar
lung
bacteri
burden
noninfluenzainfect
anim
challeng
cfu
underscor
profound
immun
defect
induc
influenza
jane
deng
unpublish
observ
number
mechan
like
contribut
impair
host
defens
respiratori
tract
bacteria
follow
viral
infect
much
understand
arisen
studi
conduct
anim
model
sequenti
infect
influenza
variou
bacteri
pathogen
comprehens
review
elsewher
henc
fundament
theme
highlight
tabl
first
influenza
respiratori
virus
due
tropism
epitheli
cell
induc
structur
alter
respiratori
epithelium
result
improv
access
lower
respiratori
tract
persist
upper
airway
bacteria
influenza
virus
reduc
human
anim
nasal
tracheal
epitheli
ciliari
function
influenza
respiratori
virus
induc
death
epitheli
cell
lead
compromis
barrier
function
airway
promot
adhes
bacteria
variou
mechan
includ
upregul
surfac
receptor
plateletactiv
factor
receptor
involv
pneumococc
invas
howev
rel
import
mechan
debat
given
respiratori
virus
induc
histolog
evid
signific
epitheli
damag
vivo
evid
inconclus
influenza
virus
also
enhanc
colon
transmiss
bacteria
studi
mice
demonstr
rate
durat
pneumococc
colon
enhanc
influenza
infect
may
mediat
type
interferondepend
mechan
addit
transmiss
bacteria
uninfect
contact
markedli
enhanc
influenza
viral
infect
donor
recipi
anim
similar
find
shown
ferret
virus
also
multipl
effect
immun
cell
includ
innat
leukocyt
critic
antibacteri
host
similarli
rsv
influenza
shown
depress
neutrophil
migrat
phagocytosi
bactericid
activ
molecular
level
one
potenti
explan
effect
sustain
macrophag
desensit
bacteri
tolllik
receptor
ligand
follow
influenza
rsv
exposur
result
decreas
neutrophil
recruit
given
ampl
evid
cell
type
essenti
clearanc
bacteri
pathogen
lung
like
influenzainduc
suppress
phagocyt
cell
popul
play
major
role
govern
suscept
secondari
bacteri
infect
anoth
emerg
theme
molecul
import
antivir
immun
may
detriment
influenzainfect
host
encount
secondari
bacteri
pathogen
activ
type
interferon
eg
ifn
b
type
ii
interferon
ifnc
innat
immun
receptor
respons
recogn
influenza
respiratori
virus
eg
tolllik
receptor
tlr
retino
acid
induc
gene
rig
shown
mediat
suscept
secondari
bacteri
infect
among
effect
immun
pathway
impair
phagocyt
cell
function
recruit
inhibit
pathway
possibl
ifninduc
suppress
gammadelta
cell
although
mechan
mainli
studi
context
primari
influenza
infect
found
simpli
induc
type
ifn
lung
intranas
administr
poli
c
ligand
rigi
suffici
impair
bacteri
clearanc
pneumonia
mrsa
suggest
mechan
may
oper
mediat
suscept
bacteria
follow
infect
respiratori
virus
addit
also
rais
possibl
host
may
experi
mild
subclin
infect
suffici
induc
antivir
immun
respons
therebi
decreas
threshold
suscept
bacteri
infect
find
need
confirm
human
studi
rais
concern
effort
focus
augment
antivir
immun
respons
strategi
treat
pandem
influenza
may
paradox
promot
develop
secondari
bacteri
infect
final
dysregul
inflamm
integr
contributor
pathogenesi
coinfect
one
hand
overli
robust
inflammatori
respons
believ
underli
lung
injuri
highli
pathogen
influenza
virus
well
influenzabacteri
coinfect
hand
imbal
antiinflammatori
mediat
may
increas
host
suscept
secondari
bacteri
pneumonia
antiinflammatori
immun
molecul
critic
regul
excess
pulmonari
inflamm
influenza
howev
elev
level
detriment
bacteri
clearanc
secondari
bacteri
pneumonia
collect
studi
illustr
consider
complex
understand
pathogenesi
polymicrobi
infect
hamper
develop
therapi
aim
restor
antibacteri
defens
follow
influenza
infect
present
immunomodulatori
therapi
aim
reduc
risk
secondari
bacteri
infect
larg
preclin
stage
develop
howev
base
upon
current
knowledg
balanc
must
struck
maintain
adequ
antivir
immun
without
compromis
antibacteri
respons
ensur
excess
inflamm
lead
lung
injuri
vaccinationreduc
burden
diseas
viralbacteri
coinfect
start
effect
vaccin
program
current
effect
vaccin
exist
h
influenza
type
b
pneumonia
influenza
effort
develop
vaccin
aureu
unsuccess
far
addit
present
vaccin
group
streptococc
speci
rsv
mani
acut
respiratori
virus
furthermor
vaccin
rate
remain
suboptim
larg
part
world
h
influenza
type
b
vaccin
introduc
countri
howev
vaccin
coverag
vari
wide
region
rang
southeast
asia
america
pneumococc
vaccin
introduc
countri
ongo
effort
world
health
organ
global
allianc
vaccin
immun
expand
vaccin
avail
global
present
countri
carri
largest
burden
bacteri
pneumonia
lowest
vaccin
rate
therefor
greatest
risk
secondari
pneumonia
influenza
pandem
present
two
type
vaccin
pneumoniaeth
polyval
conjug
vaccin
direct
serotyp
recommend
children
age
year
month
polysaccharid
vaccin
base
common
capsular
serotyp
recommend
adult
year
older
well
individu
year
old
risk
factor
pneumococc
diseas
shown
effect
reduc
invas
pneumococc
diseas
caus
vaccin
strain
eg
bacteremia
although
diseas
caus
nonvaccin
strain
becom
common
interestingli
cohort
casecontrol
studi
unit
state
elsewher
report
pneumococc
vaccin
reduc
hospit
confirm
respiratori
viral
infect
includ
influenza
human
metapneumoviru
suggest
pneumococc
infect
signific
cofactor
acut
respiratori
viral
infect
influenza
vaccin
recommend
annual
everyon
month
age
observ
studi
suggest
influenza
vaccin
reduc
hospit
rate
pneumonia
influenza
elderli
otiti
media
children
howev
definit
evid
influenza
vaccin
reduc
complic
bacteri
coinfect
difficult
come
random
trial
compar
vaccin
placebo
group
might
view
uneth
distinguish
viral
bacteri
pneumonia
difficult
even
ampl
resourc
influenza
respiratori
virus
caus
lower
respiratori
tract
diseas
exampl
retrospect
analysi
ct
scan
find
patient
lrti
demonstr
consider
overlap
find
viral
bacteri
origin
howev
diffus
airspac
diseas
commonli
associ
bacteri
infect
wherea
viral
infect
tend
airwaycentr
pattern
involv
treeinbud
find
although
product
cough
fever
chill
classic
find
bacteri
pneumonia
often
present
patient
influenza
respiratori
viral
infect
certainli
would
enabl
clinician
determin
whether
someon
viralbacteri
coinfect
rapid
microbebas
pointofcar
test
rapid
influenza
antigen
test
limit
due
rel
low
sensit
henc
much
attent
turn
toward
find
biomark
specif
bacteri
infect
test
import
individu
patient
level
also
global
health
perspect
inform
aid
clinician
decreas
unnecessari
antibiot
use
therebi
reduc
risk
antibiot
resist
two
biomark
receiv
much
attent
creactiv
protein
crp
procalcitonin
pct
detect
blood
make
attract
biomark
mainli
elev
bronchoalveolar
lavag
fluid
solubl
trigger
receptor
myeloid
cell
strem
gener
level
crp
pct
tend
higher
patient
bacteri
infect
compar
viral
infect
may
aid
clinician
determin
whether
patient
bacteri
superinfect
influenza
season
random
trial
suggest
crp
pctguid
manag
result
reduc
antibiot
usag
may
aid
priorit
patient
treatment
antibiot
short
suppli
howev
singl
test
complet
distinguish
bacteri
infect
infecti
caus
pneumonia
consider
overlap
level
patient
without
bacteri
diseas
furthermor
overlap
pct
crp
level
viral
bacteri
infect
pronounc
malariaendem
area
limit
abil
biomark
distinguish
one
type
infect
anoth
clinic
util
biomark
continu
investig
variou
respiratori
infecti
diseas
societi
around
world
issu
guidelin
treatment
lrti
includ
communityacquir
pneumonia
cap
treatment
lrti
caus
viralbacteri
coinfect
govern
region
epidemiolog
pattern
respiratori
virus
bacteria
pneumonia
h
influenza
preval
caus
communityacquir
pneumonia
worldwid
latter
occur
primarili
develop
countri
hib
vaccin
wide
avail
atyp
pathogen
chlamydia
pneumonia
mycoplasma
pneumonia
legionella
pneumophila
collect
consid
common
caus
lrti
epidemiolog
studi
carri
europ
develop
countri
exact
incid
difficult
determin
area
limit
healthcar
resourc
due
need
special
laboratori
test
specif
treatment
regimen
recommend
guidelin
often
reflect
local
antibiot
resist
pattern
guidelin
suitabl
one
regionor
even
countri
within
region
may
inappropri
anoth
exampl
unit
state
part
europ
rate
penicillinnonsuscept
ie
resist
intermedi
suscept
pneumonia
exceed
wherea
sweden
northern
european
countri
nonsuscept
rate
henc
penicillin
use
firstlin
monotherapi
treatment
cap
sweden
fluoroquinolon
betalactam
combin
macrolid
recommend
us
pneumonia
guidelin
hospit
adult
addit
microbiolog
consider
antibiot
treatment
decis
base
upon
sever
present
ie
risk
death
commonli
use
score
system
assess
risk
level
cap
confus
urea
respiratori
rate
blood
pressur
age
complic
pneumonia
sever
index
psi
includ
patient
characterist
eg
age
comorbid
symptom
sign
eg
alter
mental
statu
tachypnea
laboratori
find
guidelin
treatment
cap
use
similar
measur
divid
patient
cap
level
sever
eg
low
moder
high
sever
patient
manag
outpati
hospit
ward
icu
set
concomit
influenza
infect
suspect
children
mildtomoder
cap
otherwis
viralbacteri
interact
blackwel
publish
ltd
healthi
treat
amoxicillin
pneumonia
common
pathogen
macrolid
antibiot
atyp
bacteri
pathogen
suspect
iv
ampicillin
gener
cephalosporin
recommend
children
suspect
pneumococc
pneumonia
sick
enough
admit
regimen
also
cover
h
influenza
although
latter
necessari
blactamaseposit
strain
present
combin
therapi
macrolid
indic
atyp
pathogen
suspect
hospit
children
influenza
epidem
pandem
aureu
pyogen
addit
caus
cap
although
pyogen
cover
standard
antibiot
regimen
cap
influenza
known
circul
commun
strong
consider
made
addit
aureu
coverag
particularli
patient
sick
enough
requir
admiss
intens
care
unit
presenc
necrotizingcavitari
lesion
risk
factor
complic
cours
eg
elderli
comorbid
guidelin
made
specif
recommend
treat
secondari
bacteri
pneumonia
follow
influenza
given
frequenc
infect
certain
bacteria
particularli
aureu
increas
set
influenza
season
adult
patient
admit
cap
combin
betalactam
antibiot
fluoroquinolon
macrolid
suffici
common
cap
pathogen
eg
pneumonia
h
influenza
atyp
bacteria
also
cover
mssa
pyogen
howev
mrsa
concern
vancomycin
linezolid
start
empir
intent
discontinu
antibiot
cultur
result
return
neg
children
clindamycin
anoth
altern
mrsa
patient
symptom
upper
respiratori
infect
evid
lrti
chest
xray
cxr
may
treat
symptomat
instruct
return
symptom
worsen
mani
guidelin
emphas
influenza
respiratori
virus
frequent
caus
lrti
particularli
among
children
age
given
difficulti
distinguish
lrti
caus
viral
bacteri
mix
infect
antivir
therapi
initi
soon
possibl
patient
present
influenzalik
ill
lrti
influenza
season
prior
receiv
confirmatori
test
result
current
two
main
class
influenza
antivir
drug
adamantin
includ
amantadin
rimantadin
neuraminidas
inhibitor
oseltamivir
zanamivir
agent
wide
avail
widespread
adamantineresist
influenza
strain
includ
pandem
influenza
sever
limit
util
group
antivir
patient
milder
case
influenzalik
ill
otherwis
healthi
treatment
oseltamivir
zanamivir
recommend
start
within
hour
symptom
onset
shorten
durat
symptom
patient
admit
hospit
howev
antivir
treatment
oseltamivir
beyond
hour
symptom
onset
may
still
benefici
newer
neuraminidas
inhibitor
present
develop
undergo
clinic
trial
peramivir
administ
intraven
made
avail
unit
state
influenza
pandem
emerg
use
author
although
phase
iii
trial
unit
state
approv
use
japan
korea
theori
treatment
neuraminidas
inhibitor
might
confer
degre
protect
secondari
bacteri
infect
studi
anim
model
suggest
influenza
neuraminidas
activ
contribut
develop
bacteri
pneumonia
neuraminidas
inhibitor
reduc
suscept
influenzainfect
anim
secondari
bacteri
pneumonia
patient
present
influenzalik
symptom
influenza
known
circul
earli
treatment
neuraminidas
inhibitor
nai
may
prevent
lower
respiratori
tract
complic
influenza
although
microbiolog
data
definit
clinic
trial
nai
zanamivir
oseltamivir
suggest
patient
influenza
treat
nai
decreas
use
antibiot
infecti
complic
mainli
bronchiti
children
influenza
infect
oseltamivir
treatment
reduc
number
prescript
antibiot
observ
studi
indic
time
oseltamivir
treatment
reduc
likelihood
pneumonia
develop
although
shown
anim
model
sequenti
infect
unclear
degre
nai
decreas
risk
bacteri
pneumonia
influenzainfect
human
excess
inflamm
believ
contribut
sever
viralbacteri
coinfect
henc
interest
arisen
determin
whether
steroid
mitig
sever
lung
injuri
influenza
infect
data
pandem
use
corticosteroid
treatment
ard
fail
show
benefit
perhap
worsen
outcom
includ
death
infecti
complic
present
corticosteroid
recommend
routin
postinfluenzabacteri
pneumonia
although
studi
underway
determin
clinic
util
patient
sever
bacteri
pneumonia
consider
advanc
medic
care
occur
past
centuri
markedli
diminish
odd
anoth
influenza
pandem
bacteri
coinfect
appear
predomin
caus
death
vaccin
antibiot
improv
diagnosi
support
care
contribut
improv
outcom
viralbacteri
coinfect
nonetheless
influenza
pneumonia
remain
lead
caus
death
infecti
diseas
worldwid
bacteri
pneumonia
still
contribut
substanti
proport
death
season
pandem
influenza
outbreak
influenza
season
patient
present
sever
lrti
treat
empir
antivir
antibacteri
agent
await
result
microbiolog
test
sinc
distinguish
singl
polymicrobi
infect
problemat
improv
understand
pathogenet
mechan
respons
viralbacteri
coinfect
enabl
clinician
public
health
offici
identifi
patient
risk
develop
potenti
fatal
complic
aid
develop
therapeut
approach
aim
mitig
sever
coinfect
